Nothing to See Here

Brand-name drug companies claim that without USMCA, there's no market for biologics in Mexico. Fact: The world's largest pharmaceutical companies launched their top-selling biologics in Mexico.

View Infographic
#DoesntAddUp

If generic prescription drug prices are falling each year, why are consumer costs for prescription drugs rising?

Take Action
The Case for Competition

Now available: AAM's full 2019 Generic Drug & Biosimilars Access & Savings in the U.S. Report

Read Full Report
New White Paper: Access Denied

AAM's "Access Denied" white paper highlights new data on the treatment of generic medicines in Medicare Part D, resulting in patients paying more for their medicines even when lower-priced FDA-approved generics and biosimilars are available.

Read Press Release
How Much Did Your State Save?

Take a deeper look at state-by-state generic drug savings from the 2019 Generic Drug and Biosimilars Access & Savings in the U.S. report.

Read Blog
NAFTA 2.0: Obstacles to More Affordable Medicines

The U.S.-Mexico-Canada Agreement (USMCA) or "NAFTA 2.0" contains obstacles to more affordable meds for Americans. There is still time to #FixUSMCA to put America’s patient first!

View Infographic

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Nov 19, 2019 | Jonathan Kimball

Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA

Nov 18, 2019 | Erica Klinger

Dispensary of Hope: The Industry’s Nonprofit Supply-Chain Partner

Nov 14, 2019 | Erica Klinger

How Our Associate Members Make the World Healthier

GRx+Biosims Day 3 Healthcare Innovation and The Political Economy

Nov 11, 2019 | Erica Klinger

GRx+Biosims Year 2: The Recap

FDA - Nomination of Dr. Stephen Hahn to FDA

Nov 1, 2019 | Rachel Schwartz

AAM Statement on Nomination of Dr. Stephen Hahn to FDA

Generic Rx World Manufacturing

Oct 29, 2019 | Rachel Schwartz

AAM Testimony on the Generic Global Supply Chain—Five Takeaways